

Technology Appraisal Committee Meeting Committee D Manchester

Minutes: Confirmed

Date and Time: Thursday 23 May 2019

Present:		
	1. Professor Gary McVeigh (Chair)	Present for all notes
	2. Dr Lindsay Smith (Vice Chair)	Present for all notes
	3. Nabeel Alsindi	Present for all notes
	4. Professor Rachel Elliott	Present for all notes
	5. Dr Peter Hall	Present for all notes
	6. Rebecca Harmston	Present for all notes
	7. Dr Robert Hodgson	Present for all notes
	8. Dr Bernard Khoo	Present for all notes
	9. Dr Soo Fon Lim	Present for all notes
	10. Dr Guy Makin	Present for all notes
	11. Professor David Meads	Present for all notes
	12. Olaolu Oloyede	Present for all notes
	13. Dr Malcolm Oswald	Present for all notes
	14. Stella O'Brien	Present for all notes
In attendance:		
Lazaros Andronis	Evidence Review Group representative, Warwick Evidence	Present for notes 3 to 4
Peter Auguste	Evidence Review Group representative, Warwick Evidence	Present for notes 3 to 4
Gemma Barnacle	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Rebecca Bouch	Administrator, National Institute for Health and Care Excellence	Present for all notes
Luke Cowie	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 7
Daniel Gallacher	Evidence Review Group representative, Warwick Evidence	Present for notes 3 to 4
Christian Griffiths	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 8 to 12

Nicola Hay	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 1 to 7
Linda Landells	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Stephen Robinson	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 8 to 12
Steve Williamson	NHS England	Present for all notes
Non-public attendees:		
Alan Moore	Technical Analyst, National Institute for Health and Care Excellence	Present for all notes
Louise Jafferally	Administrator, National Institute for Health and Care Excellence	Present for all notes
Amy Crossley	Technical Analyst, National Institute for Health and Care Excellence	Present for all notes
Christian Griffiths	Technical Advisor, National Institute for Health and Care Excellence	Present for notes 1 to 7
Maroulla Whitely	Resource Impact Assessment National Institute for Health and Care Excellence	Present for all notes
Anne Greenwood	Senior Editor, National Institute for Health and Care Excellence	Present for all notes

Notes

Any other Business

1. None

Minutes from the last meeting

2. The committee approved the minutes of the committee meeting held on Tuesday 16 April 2019.

Appraisal of Dacomitinib for untreated EGFR-positive non-small-cell lung cancer [ID1346]

Part 1 – Open session

3. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Pfizer.
4. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests
 - 4.1. Peter Hall declared a personal specific financial interest as part of his team was involved in clinical research funding from AstraZeneca.
 - 4.1.1. It was agreed that this declaration would not prevent Peter Hall from participating in this section of the meeting.
 - 4.2. No further conflicts of interest were declared for this appraisal.

Part 2 – Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting)

5. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
6. The committee decision was based on consensus.
7. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of Osimertinib for untreated EGFR-positive non-small-cell lung cancer [ID1302]

Part 1 – Open session

8. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from AstraZeneca UK Ltd

9. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests

9.1. Peter Hall declared a personal specific financial interest as part of his team was involved in clinical research funding from AstraZeneca.

9.1.1. It was agreed that this declaration would not prevent Peter Hall from participating in this section of the meeting.

9.2. No further conflicts of interest were declared for this appraisal.

Part 2 – Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting)

10. Agreement on the content of the Final Appraisal Determination (FAD) was discussed by the committee.

11. The committee decision was based on consensus.

12. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.